PDCD1 / CD279 Molecule
PD-1 / PDCD1 Molecule Synonym Name
PD-1 / PDCD1 Protein Products
PD-1 / PDCD1 Antibody Products
|Cat No||Species||Product Description|
|PD1-BNA001||Human||Biotinylated Anti-PD-1 Neutralizing Antibody|
|PD1-NA001||Human||Anti-PD-1 Neutralizing Antibody|
PD-1 / PDCD1 Molecule Background
Programmed cell death protein 1 (PD-1) is also known as CD279 and PDCD1, is a type I membrane protein and is a member of the extended CD28/CTLA-4 family of T cell regulators. PDCD1 is expressed on the surface of activated T cells, B cells, macrophages, myeloid cells and a subset of thymocytes. PD-1 has two ligands, PD-L1 and PD-L2, which are members of the B7 family. PD-L1 is expressed on almost all murine tumor cell lines, including PA1 myeloma, P815 mastocytoma, and B16 melanoma upon treatment with IFN-γ. PD-L2 expression is more restricted and is expressed mainly by DCs and a few tumor lines. PD1 inhibits the T-cell proliferation and production of related cytokines including IL-1, IL-4, IL-10 and IFN-γ by suppressing the activation and transduction of PI3K/AKT pathway. In addition, coligation of PD1 inhibits BCR-mediating signal by dephosphorylating key signal transducer. In vitro, treatment of anti-CD3 stimulated T cells with PD-L1-Ig results in reduced T cell proliferation and IFN-γ secretion. Monoclonal antibodies targeting PD-1 that boost the immune system are being developed for the treatment of cancer.
- (1) Ishida Y., et al., 1992, EMBO J. 11 (11): 3887–95.
- (2) Blank C., et al., 2007, Cancer Immunol. Immunother. 56 (5): 739–45.
- (3) Agata Y., et al., 1996, Int. Immunol. 8 (5): 765–72.
- (4) Freeman GJ., et al., 2000, J. Exp. Med. 192 (7): 1027–34.
- (5) Latchman Y., et al., 2001, Nat. Immunol. 2 (3): 261–8.
- (6) Yamazaki T., et al., 2002, J. Immunol. 169 (10): 5538–45.